• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS)
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Life sciences
  • Skip More from NICE submenu

    Explore more from NICE

    • What NICE does
    • About us
    • Reusing our content
    • Implementing NICE guidance
    • News, blogs and podcasts
    • Contact us
    • Get involved
    • Careers

    • Join a committee
    • Comment on a consultation

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Gynaecological conditions
  5. Heavy menstrual bleeding

Heavy menstrual bleeding: assessment and management

  • NICE guideline
  • Reference number: NG88
  • Published:  14 March 2018
  • Last updated:  24 May 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Research recommendations coming out of this guidance

  • Hysteroscopy compared with ultrasound or empiric pharmacological treatment in the diagnosis and management of heavy menstrual bleeding (HMB): -Is initial testing using hysteroscopy more effective than testing with pelvic ultrasound or empiric pharmacological treatment in the diagnosis and management of HMB?

  • Effectiveness of the progestogen-only pill, injectable progestogens, or progestogen implants in alleviating HMB:- How effective are the progestogen-only pill, injectable progestogens or progestogen implants in alleviating HMB?

  • Long-term outcomes of pharmacological and uterine-sparing surgical treatments for HMB associated with adenomyosis:- What are the long-term clinical outcomes of pharmacological and uterine-sparing surgical treatments in women with HMB associated with adenomyosis?

  • Hysteroscopic removal of submucosal fibroids compared with other uterine-sparing treatments for HMB:- Is hysteroscopic removal of submucosal fibroids more effective and cost-effective than other uterine-sparing treatments for the management of HMB?

  • Second-generation endometrial ablation for HMB associated with myometrial pathology:- Are outcomes after second-generation endometrial ablation for women with HMB associated with myometrial pathology (adenomyosis and/or uterine fibroids) equivalent to those for women without myometrial pathology?

Back to top
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS) Clinical Knowledge SummariesClinical Knowledge Summaries
  • British National Formulary (BNF) British National FormularyBritish National Formulary
  • British National Formulary for Children (BNFC) British National Formulary for ChildrenBritish National Formulary for Children
  • Life sciences
  • Library and knowledge services
  • What NICE does
  • Implementing NICE guidance
  • Get involved
  • About us
  • Careers
  • News, blogs and podcasts
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.